NYSEARCA:IHI

ISHARES DOW JONES US MEDICAL DEV.(ETF) (IHI)

52.11
+0.23 (0.44%)
as of Jul 6, 2026, 8:00:00 pm Market Open.
64 watching
0
Investor Insights
star iconJul 6, 2026, 12:00 am

This summary was created by AI, based on 1 opinions in the last 12 months.

The iShares Dow Jones US Medical Devices ETF (IHI-N) presents a compelling investment opportunity within the healthcare sector, which is currently experiencing challenges but is not perceived as a value trap by experts. Despite being the worst-performing sector this year, many analysts suggest that the worst may be over, indicating that the bottom has likely been reached. With the market facing high valuations and potential volatility due to inflation concerns, healthcare stands out as a more stable option, particularly due to its resilience against interest rate fluctuations. For investors wary of political influences on pharmaceuticals, focusing on healthcare equipment and services, such as IHI, can be a prudent choice for long-term growth. Overall, the sentiment points toward a recovery phased in an essential industry.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
AMGN,AMGN
PAST TOP PICK
(A Top Pick Jun 08/18, Up 11%) He continues to love holding this. Worldwide hospital spending continues to increase.
BUY
He likes this. Medical devices play to an aging demographic. The risk is political intereference with governments issuing new laws that interfere with this sector.
PAST TOP PICK
(A Top Pick May 09/18, Up 16%) He sees this continuing to be a good performer. It will follow the market up and down, but will do a little better in the long run. The ETF helps reduce the risk of picking a single company. He has backed away from healthcare, but still still holds this.
PAST TOP PICK
(A Top Pick Apr 11/18, Up 25%) It is high quality with a 1.0 beta. He would stick with it as the fundamental still hold true -- aging population, diabetes, etc. There are 29 million US adults with Type 2 diabetes and another 84 million are pre-diabetic -- almost 1 in 3 adults.
BUY
He likes because it gives diversification away from the big pharma. Nothing wrong with this one.
BUY
IXJ vs. IHI IXJ is well-diversified and global and prefers this to IHI. It has an overlay of healthcare technology, which is exciting particularly technology. IHI is fine, too. Buy one-third IXJ and one-third IHI.
BUY
IXJ vs. IHI IXJ is well-diversified and global and prefers this to IHI. It has an overlay of healthcare technology, which is exciting particularly technology. IHI is fine, too. Buy one-third IXJ and one-third IHI.
PAST TOP PICK
(A Top Pick Nov 23/18, Up 6%) Nov.25-Feb.14 is seasonality which coincides with several healthcare conferences. These medical stocks are still outperforming the market. He took profits.
COMMENT
What comes screaming back is the previous leaders. There is persistence. Internet retail is the first one to break down and the first one to reverse. Basic materials are the area starting to make a turn. It would be complimentary to add some Canada.
TOP PICK
He likes the end-market growth story -- knees, hips, joints, etc. High-quality with a high market beta -- this is not a defensive ETF. A broad basket with a diversified portfolio. Yield 0.36%
PAST TOP PICK
(A Top Pick Jan 11/18, Up 8%) Likes it. There are really two robust parts of the healtcare sector, one is this one, medical devices and equipment, and the other is managed care. You are buying market beta here; if the market goes down, IHI is going down. They might be high quality and good cash flow, but don't think of this as safety. Loves it and would stick with it.
TOP PICK
Healthcare has performed phenomally this year, avoiding cyclical breakdowns found in other sectors. Seasonally, it's Nov.24-Feb.14. Aging demographics help, but really pushes this are all the healthcare conferences at the start of the year. These stocks run up till then.
TOP PICK
He likes medical devices – worldwide hospital spending, changing demographics. It has great tailwinds. They are less politically charged than drug prices.
TOP PICK

He likes the healthcare space. This is a high-quality beta play in the space. Don’t expect it to be super defensive, but thinks global hospital spending will continue to rise.

TOP PICK

It's feeding into the demographic of aging baby boomers. This includes medical devices like Abbott Labs. Also likes it because it's U.S. and diversifies from big pharma.

Showing 16 to 30 of 45 entries